Roger Zoorob
Has grant
Richard M. Kleberg, Sr. Professor and Chair
Research Interests
Explore related searches
Contact this professor
Get a free first email built on one of their papers, ready for you to edit and send yourself.
About
Dr. Roger Zoorob is the Richard M. Kleberg, Sr. Professor and Chair at Baylor College of Medicine in the United States. His research areas focus on antibiotic resistance, primary care patient behaviors regarding antibiotic use, and the impact of healthcare worker experiences during the COVID-19 pandemic. Dr. Zoorob has also explored cancer trends and healthcare disparities, particularly in relation to smoking cessation and screening programs.
Recent Grants
Grant: Close
Come Home Houston
Open Date: 2020-04-01
Close Date: 2025-04-01
Grant: Close
Bringing Alcohol and Other Drug Research to Primary Care
Open Date: 2020-04-01
Close Date: 2024-03-01
Grant: Close
ringing Alcohol and Other Drug Research to Primary Care
Open Date: 2020-04-01
Close Date: 2024-03-01
Grant: Close
AWARE-HOUSTON/MHAT
Open Date: 2020-04-01
Close Date: 2023-04-01
Grant: Close
Project REACH: Improve HIV and Hepatitis C prevention, screening and access to recovery services for individuals with a substance use disorder and/or co-occurring substance use and mental health disorders
Open Date: 2018-09-01
Close Date: 2023-09-01
Articles (13)
Background Risk factors for ciprofloxacin or MDR in primary care urine specimens are not well defined. Objectives We created a primary care-specific antibiogram for Escherichia coli isolates from cases with complicated and uncomplicated urinary tract infection (UTI) and evaluated risk factors for ciprofloxacin, trimethoprim/sulfamethoxazole and MDR among Enterobacterales. Methods We conducted a cross-sectional study to determine resistance and risk factors by collecting urine cultures from all patients (≥18 years) presenting with provider-suspected UTI at two primary care, safety-net clinics in Houston, TX, USA between November 2018 and March 2020. Results Among 1262 cultures, 308 cultures grew 339 uropathogens. Patients with Enterobacterales (n = 199) were mostly female (93.5%) with a mean age of 48.5 years. E. coli was the predominant uropathogen isolated (n = 187/339; 55%) and had elevated trimethoprim/sulfamethoxazole (43.6%) and ciprofloxacin (29.5%) resistance, low nitrofurantoin (1.8%) resistance, and no fosfomycin resistance. Among E. coli, 10.6% were ESBL positive and 24.9% had MDR. Birth outside the U.S.A., prior (2 year) trimethoprim/sulfamethoxazole resistance, and diabetes mellitus were associated with trimethoprim/sulfamethoxazole resistance. Prior (60 day) fluoroquinolone use, prior ciprofloxacin resistance and both diabetes mellitus and hypertension were strongly associated with ciprofloxacin resistance. Prior fluoroquinolone use and a history of resistance to any studied antibiotic were associated with MDR, while pregnancy was protective. Conclusions We found elevated resistance to UTI-relevant antimicrobials and novel factors associated with resistance; these data can be incorporated into clinical decision tools to improve organism and drug concordance.
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Year:
2022
Year:
2022
Year:
2021
Year:
2021
Year:
2021
Year:
2020
Year:
2020
Year:
2020
Year:
2020
Collaborators (4)
Barbara Trautner
Baylor College of Medicine
Maria Carmenza Mejia
Associate Professor
Baylor College of Medicine
Jacqueline Hirth
Assistant Professor
Baylor College of Medicine
Larissa Grigoryan
Baylor College of Medicine
Make your next move.
Prepare your application
Review drafts before you send them.